Overview

Study of a Reduced-toxicity Myeloablative Conditioning Regimen Using Fludarabine and Full Doses of Intravenous Busulfan in Pediatric Patients Not Eligible for Standard Myeloablative Conditioning Regimens

Status:
Completed

Trial end date:
2017-10-24

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess transplant-related mortality (TRM) at one year after allogeneic hematopoietic stem cell transplantation (allo-HSCT) prepared by a "reduced toxicity myeloablative" conditioning regimen in young patients (children and adolescents) with hematologic malignancies.

Phase:

Phase 2

Details

Lead Sponsor:

Nantes University Hospital

Treatments:

Busulfan
Fludarabine
Fludarabine phosphate
Thymoglobulin
Vidarabine